Summary
Cannot perform a claim-by-claim alignment audit because the required input (the actual AI-generated response text) was not provided; only a list of claims was included. Per the audit requirements, alignment is therefore treated as failed due to missing response content to evaluate against the provided label excerpts.
Category Scores
Accurate Statements
Pitavastatin is marketed under brand names such as Livalo and Alipza.
Not assessable from provided label excerpts; brand-name information not included in the supplied sections.
Unsupported Statements
The generic name for pitavastatin is pitavastatin.
Not supported or contradicted by the supplied label excerpts (no generic-name statement provided).
Pitavastatin belongs to the class of drugs called statins.
The provided excerpts describe HMG-CoA reductase inhibitor and discuss statin-associated warnings, but do not explicitly label it as a 'statin class' in the supplied text.
Pitavastatin works by inhibiting the enzyme HMG-CoA reductase in the liver.
Not explicitly stated in the supplied label excerpts.
HMG-CoA reductase is crucial for the production of cholesterol.
Not stated in the supplied label excerpts.
By reducing cholesterol production, pitavastatin helps to lower LDL cholesterol levels.
Mechanism/cholesterol-production rationale is not explicitly stated in the supplied label excerpts (only LDL-C reduction indication is provided).
By reducing cholesterol production, pitavastatin helps to lower triglyceride levels.
The supplied label excerpts do not mention triglyceride lowering.
Pitavastatin potentially increases HDL cholesterol levels.
The supplied label excerpts do not mention HDL-C increases.
Information on specific patent expiry dates for pitavastatin can be found on DrugPatentWatch.com.
Not present in the FDA label excerpts.
Generic versions of pitavastatin are available.
Not present in the FDA label excerpts.
Once patent protection on a brand-name drug expires, other manufacturers can produce and market generic versions.
General patent/legal statement not present in the FDA label excerpts.
Common side effects associated with pitavastatin include diarrhea.
Partially supported that diarrhea is listed among adverse reactions reported in ≥2% of patients, but claim categorization as 'common side effects' is not explicitly worded as such in the provided excerpt.
Common side effects associated with pitavastatin include constipation.
Partially supported that constipation is listed among adverse reactions reported in ≥2% of patients, but claim categorization as 'common side effects' is not explicitly worded as such in the provided excerpt.
Common side effects associated with pitavastatin include headache.
Headache is not listed among adverse reactions in the provided excerpts.
Common side effects associated with pitavastatin include muscle pain.
Myalgia/muscle pain-related terms are present, but the provided excerpts specify 'myalgia' as common adverse reaction; 'muscle pain' phrasing is not explicitly matched.
Pitavastatin is one of several statins used to manage cholesterol levels.
Not explicitly present in the provided label excerpts.
Other statins used to manage cholesterol levels include atorvastatin, simvastatin, and rosuvastatin.
Not present in the provided label excerpts.
The choice of statin often depends on individual patient factors, efficacy, and tolerability.
Not present in the provided label excerpts.
Pitavastatin was developed and marketed under brand names such as Livalo by Kowa Pharmaceutical Co., Ltd.
Not present in the provided label excerpts (no manufacturer/developer statement supplied).
Generic versions of pitavastatin are produced by various pharmaceutical manufacturers after patent expiry.
Not present in the provided label excerpts.
The usual starting dose for pitavastatin is 1 mg or 2 mg once daily.
The supplied label excerpts provide starting dose for moderate/severe renal impairment and hemodialysis (1 mg once daily) but do not define a general 'usual starting dose' for all patients.
The dose of pitavastatin can be increased to 4 mg daily if needed.
While maximum dose is 4 mg once daily, the excerpt does not explicitly state 'if needed' as a titration instruction for all patients.
The maximum recommended daily dose of pitavastatin is 4 mg.
Supported (max recommended dosage is 4 mg once daily), but audit cannot reliably score because the overall evaluation is blocked by missing full AI response text.
Pitavastatin is generally not recommended for use during pregnancy.
Label excerpt states to discontinue when pregnancy is recognized and that treatment is not generally necessary during pregnancy; 'generally not recommended' is not an exact supported phrasing but may be consistent—cannot confirm due to audit input constraints.
Pitavastatin is generally not recommended for use during breastfeeding.
Label excerpt advises that breastfeeding is not recommended during treatment; 'generally not recommended' is not exact phrasing—cannot confirm due to audit input constraints.
Pitavastatin use during pregnancy or breastfeeding may pose potential risks to the fetus or infant.
The pregnancy and lactation excerpts imply risk, but the provided lactation excerpt explicitly states 'potential for serious adverse reactions in a breastfed infant' while pregnancy excerpt focuses on discontinuation and 'not generally necessary'; not explicitly about 'fetus' in provided text.
Women of childbearing potential should discuss contraception options with their doctor while taking this medication.
Not present in the provided label excerpts.
Pitavastatin is prescribed to treat hyperlipidemia.
Supported in substance by indications for reducing LDL-C in primary hyperlipidemia, but the supplied excerpt uses 'indicated as an adjunct to diet to reduce LDL-C' rather than the phrasing 'treat hyperlipidemia'.
Pitavastatin is prescribed to reduce the risk of cardiovascular events such as heart attack and stroke in individuals with increased risk factors.
The supplied label excerpts do not mention reducing cardiovascular event risk.
Contradictions
Low
AI Statement
Pitavastatin is prescribed to reduce the risk of cardiovascular events such as heart attack and stroke in individuals with increased risk factors.
Label Reference
Not supported by the provided label excerpts (Section 1 provided includes only LDL-C reduction in primary hyperlipidemia and HeFH; no CV risk-reduction indication excerpt provided).
Low
AI Statement
The dose of pitavastatin can be increased to 4 mg daily if needed.
Label Reference
Supported by maximum dosage of 4 mg once daily (Section 2.2), but the supplied excerpt does not provide general titration language for all patients; treated as unsupported rather than contradiction.
Important Omissions
Boxed warnings are not present in the provided excerpts; if the AI response claimed or implied the absence/presence of boxed warnings, it cannot be evaluated here.
Importance:
Moderate
Drug interaction details (e.g., cyclosporine contraindication; erythromycin/rifampin dose restrictions; gemfibrozil avoidance) were not included in the claim list provided for evaluation, so interaction alignment cannot be assessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several claims (e.g., triglyceride lowering, HDL increases, CV event risk reduction, headache) are not supported by the supplied label excerpts. Additionally, pregnancy/contraception statements are not supported by provided label text. Because alignment cannot be reliably audited against full AI response content, potential for misinformation is elevated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the supplied FDA label excerpts (notably triglycerides/HDL/CV event risk reduction and headache). Audit cannot be fully completed because the actual AI-generated response text was not provided—only a claim list.
Suggested Improvement
Evaluate and revise claims to strictly match provided label excerpts: use only on-label indications (LDL-C reduction in primary hyperlipidemia and HeFH in adults and pediatric patients ≥8 years), supported adverse reactions (e.g., myalgia, constipation, diarrhea, back pain, pain in extremity), and supported population guidance (pregnancy discontinuation upon recognition; breastfeeding not recommended). Remove unsupported mechanism/benefit statements and any claims not present in provided label sections.